Development

The seven chosen sponsors will help accelerate development of novel drugs and biologics for rare diseases.

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Vabysmo, already approved for patients with RVO in the US and Japan, would be the first bispecific antibody treatment for the condition in Europe.

The typical cycle of ceasing and then reinitiating fremanezumab treatments may actually result in increased monthly migraine days, the study said.

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

GRPR, or gastrin-releasing peptide receptor, is part of the bombesin G protein-coupled receptor family and has been found to be overexpressed in multiple cancers.

Results of a Phase III trial showed that Tagrisso with the addition of chemotherapy reduced the risk of disease progression or death associated with EGFR-mutated non-small cell lung cancer by 44%.

Imfinzi (durvalumab) combined with chemotherapy decreased the risk of disease progression or death by 58% in a 700-patient trial.

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.

Gabi Hanna, MD, CEO and co-founder of Lamassu Pharma talks about a novel oncology platform and the link between science and patient care.

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Key information is needed for excipients and their potential impact on continuous manufacturing processes.

Syngene's new production platform offers rapid protein synthesis with lower risk.

At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with Pharmaceutical Technology to discuss the firm’s MODEL platform and its potential impact on therapeutic delivery for brain-related conditions.

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.

Webinar Date/Time: Wednesday, July 10, 2024 - 11am EDT | 4pm GMT | 5pm CEST

A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

Webinar Date/Time: Thu, Jun 27, 2024 11:00 AM EDT

Webinar Date/Time: Thursday, June 20, 2024 - 11am EDT | 4pm GMT | 5pm CEST

Webinar Date/Time: Thu, Jun 20, 2024 11:00 AM EDT

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Webinar Date/Time: Mon, Jun 24, 2024 11:00 AM EDT